Bio intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs. ・This ...

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced ...

Funding expected to provide cash runway into 2026 98% of investment in private placement from Pre-IPO and/or IPO investors Data update from OST-HER2 Phase 2b clinical trial in recurrent, resected ...

Private placement securities continue to offer insurers attractive opportunities to enhance portfolio income, according to a recent Conning report. Conning’s latest Viewpoint commentary, “Private ...

KALA BIO, Inc. announces $10.75 million private placement to advance clinical development of KPI-012 for severe eye diseases. KALA Bio, Inc., a clinical-stage biopharmaceutical company focused on ...

Just as with private placements of equity, issuing bonds privately requires careful attention to federal law. Bonds are usually classified as "securities," triggering various regulatory requirements.

Tenax Therapeutics, Inc. has announced a private placement financing agreement with RTW Investments that is expected to generate approximately $25 million in gross proceeds. This financing will ...

COLLECTIVE METALS INC. (CSE: COMT | OTC: CLLMF | FSE: TO1) (the 'Company” or 'Collective”) is pleased to announce that it has amended the terms of its non-brokered private placement financing for ...

Rule 144A and Regulation D offer exemptions from federal securities registration requirements under the Securities Act of 1933. However, they apply to different situations, and overseas companies must ...